Call Us Toll Free: 1-800-388-9993

_______________________

Dear DRIP Investors,


We have been helping people enroll in DRIPs since 1986. Many of our subscribers have written to express their thanks and describe the outcome of their DRIP investments. It has been a source of pride and our great pleasure to have assisted in your efforts to secure financial security.


However, after 35 years we have decided to stop fulfilling orders for enrollments after the March cycle. Moneypaper, via the directinvesting.com website, will continue to provide information about DRIPs and the enrollment process.


As always, good luck,

Vita Nelson


 

 

 

 

Eli Lilly & Company (LLY)

Available from the Temper Enrollment Service: No


Last Update On: 01/07/2021:

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes osteoporosis in postmenopausal women and men and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain migraine and episodic cluster headache attention-deficit hyperactivity disorder and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation Pfizer Inc. Dicerna Pharmaceuticals, Inc. AC Immune SA Centrexion Therapeutics Corporation ImmuNext, Inc. Avidity Biosciences, Inc. Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction AbCellera Biologics Inc. and Sermonix Pharmaceuticals Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. **Taken from Yahoo Finance**

Industry: Drugs
Minimum Investment: $50.00
Maximum Investment: 150,000/year
Shares to qualify: 1
Recent Price: 187.05
Investing Fee: $5+3¢/sh.
Fee for Dividends: 3% to $3+3¢/sh.

! = Company pays fees

Information is based on an annual survey and updated when company changes become available.

Click for Español

FOR MORE
INFORMATION

And a free copy of The Moneypaper's direct investing brochure, please enter your contact information below.

You will also be signed up to receive our monthly stock special.

You can unsubscribe at any time. We do not share your email with anyone.

By email, you get the Monthly “Stock Special,” where the service fee for enrollment in a great DRIP stock is reduced.

* Required Field.